Treatments for childhood Burkitt lymphoma

The following are treatment options for childhood Burkitt lymphoma. The healthcare team will suggest treatments based on your child’s health and specific information about the lymphoma. Treatments are often based on the stage or risk group.

Treatments for newly diagnosed childhood Burkitt lymphoma

Chemotherapy is the main treatment for newly diagnosed childhood Burkitt lymphoma. Surgery to remove the tumour may be done before chemotherapy if the tumour is only in one area of the body, such as the abdomen.


Chemotherapy is the main treatment for childhood Burkitt lymphoma. How long chemotherapy is given depends on the stage, risk group and treatment plan (protocol). Chemotherapy may be given for 9 weeks to 6 months for stage 1 or 2 Burkitt lymphoma and for 6 to 8 months for stage 3 or 4 Burkitt lymphoma. How long treatments last can vary depending on how your child responds to treatment and copes with side effects of treatment.

Chemotherapy drugs are given in different combinations based on different treatment plans. The most common chemotherapy drugs used in combinations for Burkitt lymphoma include:

  • cyclophosphamide (Procytox)
  • vincristine (Oncovin)
  • prednisone
  • cytarabine (Cytosar)
  • etoposide (Vepesid, VP-16)
  • methotrexate
  • prednisolone
  • doxorubicin (Adriamycin)
  • hydrocortisone
  • dexamethasone (Decadron, Dexasone)
  • daunorubicin (Cerubidine, daunomycin)
  • asparaginase (Kidrolase)
  • mercaptopurine (Purinethol)
  • thioguanine (Lanvis)

Intrathecal chemotherapy may be given to prevent the spread of Burkitt lymphoma to the brain and spinal cord (called the central nervous system, or CNS) or to treat Burkitt lymphoma that has spread to the CNS. This means that the drugs are given directly into the cerebrospinal fluid (CSF) around the brain and spinal cord. Intrathecal chemotherapy can include 1 to 3 of the following drugs:

  • methotrexate
  • hydrocortisone
  • cytarabine

Targeted therapy

Targeted therapy with rituximab (Rituxan) may be used in combination with chemotherapy to treat children with Burkitt lymphoma.

Treatments for recurrent childhood Burkitt lymphoma

Treatments for recurrent (relapsed) childhood Burkitt lymphoma may include more intense chemotherapy, with or without targeted therapy (such as rituximab), and an allogeneic or autologous stem cell transplant. Immunotherapy with immune checkpoint inhibitors or CAR T-cell therapy may be used in a clinical trial to treat recurrent Burkitt lymphoma.

Chemotherapy combinations used for recurrent childhood Burkitt lymphoma include:

  • ifosfamide (Ifex), carboplatin (Paraplatin, Paraplatin AQ), etoposide and rituximab

Clinical trials

Children with cancer may be treated in a clinical trial. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • Allen CE, Kamdar KY, Bollard CM, Gross TG . Malignant non-Hodgkin lymphomas in children. Pizzo PA & Poplack DG (eds.). Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia: Wolters Kluwer; 2016: 23: 587-603.
  • American Cancer Society. Treating Non-Hodgkin Lymphoma in Children. 2017.
  • Gross TG & Perkins SL . Malignant non-Hodgkin lymphomas in children. Pizzo, P. A. & Poplack, D. G. (Eds.). Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 23:pp. 663-682.
  • Johnston JM. Pediatric Non-Hodgkin Lymphoma Treatment and Management. 2018.
  • National Cancer Institute. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) Patient Version. 2018.
  • National Cancer Institute. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) Health Professional Version. 2018.
  • Truong TH, Weitzman, S, Arceci RJ . Non-Hodgkin lymphoma of childhood. Wiernik PH, Goldman JM, Dutcher JP & Kyle RA (eds.). Neoplastic Diseases of the Blood. 5th ed. Springer; 2013: 48: pp. 1049-1072.
  • Woods D, McDonald, L . Non-Hodgkin lymphoma. Baggott C, Fochtman D, Foley GV & Patterson Kelly, K (eds.). Nursing Care of Children and Adolescents with Cancer. 4rd ed. APHON; 2011: 29: pp. 1023-1037.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on, nor do we endorse any service, product, treatment or therapy.

1-888-939-3333 | | © 2024 Canadian Cancer Society